nach oben

Erschienen in:

10.06.2020 | Original Article

Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation

verfasst von: Satoshi Kaito, Atsushi Wada, Hiroto Adachi, Ryosuke Konuma, Yuya Kishida, Akihito Nagata, Tatsuya Konishi, Yuta Yamada, Takuma Kumagai, Kota Yoshifuji, Junichi Mukae, Megumi Akiyama, Kyoko Inamoto, Takashi Toya, Aiko Igarashi, Yuho Najima, Hideharu Muto, Takeshi Kobayashi, Kazuhiko Kakihana, Kazuteru Ohashi, Hisashi Sakamaki, Noriko Doki

Erschienen in: Annals of Hematology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Second allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a low survival outcome and a high non-relapse mortality (NRM) rate which is a major obstacle to this treatment. We hypothesized that the status of malnourishment after first allo-HSCT as represented by the geriatric nutritional risk index (GNRI) could be used as a prognostic factor to determine the outcomes of second allo-HSCT. A total of 108 patients with a median age of 42 (range, 17–69) years, who received second allo-HSCT for disease recurrence after first allo-HSCT from our institution, were included in this study. Low GNRI had a significant impact on NRM at 2 years after second allo-HSCT: 56.9% in patients with GNRI ≤ 92 compared with 27.5% in patients with GNRI > 92 (P = 0.002). In multivariate analysis, GNRI of ≤ 92 was the only significant factor for NRM (hazard ratio [HR] 2.29, 95% confidence interval [CI] 1.15–4.56, P = 0.018). High-risk disease status at second allo-HSCT (HR 2.74, 95% CI 1.46–5.14, P = 0.002) and GNRI of ≤ 92 (HR 1.70, 95% CI 1.02–2.82, P = 0.042) were identified as significant factors for overall survival (OS). A score of 1 was assigned to each factor, and the OS rate at 2 years after second allo-HSCT decreased according to the score: 53.0% in patients with score 0, 32.3% with score 1, and 2.5% with score 2 (P < 0.001). In conclusion, GNRI could be a useful predictor for the outcomes of second allo-HSCT. A prospective study in other cohorts is warranted to validate the findings of our study.

Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D (2010) NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the epidemiology and natural history of relapse following allogeneic cell transplantation. Biol Blood Marrow Transplant 16:871–890PubMedPubMedCentralCrossRef

Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH et al (2010) NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16:1467–1503PubMedPubMedCentralCrossRef

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D (2009) Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 15:30–38PubMedCrossRef

Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E (2009) Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 15:1431–1438PubMedPubMedCentralCrossRef

Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Armand P (2013) Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19:1713–1718PubMedCrossRef

Kishi K, Takahashi S, Gondo H, Shiobara S, Kanamaru A, Kato S, Hirabayashi N, Moriyama Y, Harada M, Asano S, Hara H, Shibata A (1997) Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 19:461–466PubMedCrossRef

Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N, et al (2000) Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM) Br J Haematol 108:400–407

Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E, Alessandrino PE, Locatelli F, Vernant JP, Sierra J, Jouet JP, Frassoni F, for the Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (2001) Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European cooperative group for blood and marrow transplantation. J Clin Oncol 19:3675–3684PubMedCrossRef

Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringdén O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34:721–727PubMedCrossRef

10.

Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA, Littlewood TJ, Milligan DW, Pagliuca A, Thomson KJ, Marks DI, Russell NH (2008) Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 42:783–789PubMedCrossRef

11.

Kedmi M, Resnick IB, Dray L, Aker M, Samuel S, Gesundheit B, Slavin S, Or R, Shapira MY (2009) A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant 15:483–489PubMedCrossRef

12.

Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhauser M et al (2013) Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol 31:3259–3271PubMedCrossRef

13.

Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P et al (2015) Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant 50:1542–1550PubMedCrossRef

14.

Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A, Michallet M, Santarone S, Ehninger G, Polge E, Laszlo D, Schmid C, Nagler A, Mohty M (2015) Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 10 years. Bone Marrow Transplant 50:1508–1512PubMedCrossRef

15.

Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, Cabrera Marin JR, Espigado I, Solano C, Ferrà C, García-Noblejas A, Jimenez S, Sampol A, Yañez L, García-Gutiérrez V, Pascual MJ, Jurado M, Moraleda JM, Valcarcel D, Sanz MA, Carreras E, Duarte RF (2016) Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Espanol de Trasplante Hematopoyetico. Biol Blood Marrow Transplant 22:584–588PubMedCrossRef

16.

Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M, Ehninger G, Lioure B, Schaap N, Afanasyev B, Yeshurun M, Isaksson C, Maertens J, Chalandon Y, Schmid C, Nagler A, Mohty M (2018) Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol 4:1245–1253PubMedCrossRef

17.

El-Ghammaz AMS, Ben Matoug R, Elzimaity M, Mostafa N (2017) Nutritional status of allogeneic hematopoietic stem cell transplantation recipients: influencing risk factors and impact on survival. Support Care Cancer 25:3085–3093PubMedCrossRef

18.

Brotelle T, Lemal R, Cabrespine A, Combal C, Hermet E, Ravinet A, Bay JO, Bouteloup C (2018) Prevalence of malnutrition in adult patients previously treated with allogeneic hematopoietic stem-cell transplantation. Clin Nutr 37:739–745PubMedCrossRef

19.

Chandra RK (1997) Nutrition and the immune system: an introduction. Am J Clin Nutr 66:460s–463sPubMedCrossRef

20.

Bourke CD, Berkley JA, Prendergast AJ (2016) Immune dysfunction as a cause and consequence of malnutrition. Trends Immunol 37:386–398PubMedPubMedCentralCrossRef

21.

Kaito S, Sekiya N, Najima Y, Suzuki T, Wada A, Adachi H, Konuma R, Kishida Y, Nagata A, Konishi T, Yamada Y, Kumagai T, Inamoto K, Yoshifuji K, Akiyama M, Toya T, Igarashi A, Muto H, Doki N, Kobayashi T, Kakihana K, Ohashi K (2020) Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 55:661–664 PubMedCrossRef

22.

Buzby GP, Knox LS, Crosby LO, Eisenberg JM, Haakenson CM, McNeal GE et al (1988) Study protocol: a randomized clinical trial of total parenteral nutrition in malnourished surgical patients. Am J Clin Nutr 47:366–381PubMedCrossRef

23.

Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, Benazeth S, Cynober L, Aussel C (2005) Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 82:777–783CrossRefPubMed

24.

Kanemasa Y, Shimoyama T, Sasaki Y, Hishima T, Omuro Y (2018) Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. Ann Hematol 97:999–1007PubMedCrossRef

25.

Yamada K, Furuya R, Takita T, Maruyama Y, Yamaguchi Y, Ohkawa S, Kumagai H (2008) Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr 87:106–113CrossRefPubMed

26.

Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K, Yamamoto K (2013) Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 77:705–711CrossRefPubMed

27.

Gu W, Zhang G, Sun L, Ma Q, Cheng Y, Zhang H, Shi G, Zhu Y, Ye D (2015) Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma. J Cachexia Sarcopenia Muscle 6:222–230PubMedPubMedCentralCrossRef

28.

Bo Y, Wang K, Liu Y, You J, Cui H, Zhu Y, Lu Q, Yuan L (2016) The geriatric nutritional risk index predicts survival in elderly esophageal squamous cell carcinoma patients with radiotherapy. PLoS One 11:e0155903PubMedPubMedCentralCrossRef

29.

Miyake H, Tei H, Fujisawa M (2017) Geriatric nutrition risk index is an important predictor of cancer-specific survival, but not recurrence-free survival, in patients undergoing surgical resection for non-metastatic renal cell carcinoma. Curr Urol 10:26–31PubMedPubMedCentralCrossRef

30.

Shoji F, Miura N, Matsubara T, Akamine T, Kozuma Y, Haratake N, Takamori S, Katsura M, Takada K, Toyokawa G, Takenaka T, Yamazaki K, Okamoto T, Takeo S, Maehara Y (2018) Prognostic significance of immune-nutritional parameters for surgically resected elderly lung cancer patients: a multicentre retrospective study. Interact Cardiovasc Thorac Surg 26:389–394PubMedCrossRef

31.

Li L, Wang H, Yang J, Jiang L, Yang J, Wu H, Wen T, Yan L (2018) Geriatric nutritional risk index predicts prognosis after hepatectomy in elderly patients with hepatitis B virus-related hepatocellular carcinoma. Sci Rep 8:12561PubMedPubMedCentralCrossRef

32.

Yoshihisa A, Kanno Y, Watanabe S, Yokokawa T, Abe S, Miyata M, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Suzuki H, Ishida T, Takeishi Y (2018) Impact of nutritional indices on mortality in patients with heart failure. Open Heart 5:e000730PubMedPubMedCentralCrossRef

33.

Sasaki H, Nagano S, Komiya S, Taniguchi N, Setoguchi T (2018) Validation of different nutritional assessment tools in predicting prognosis of patients with soft tissue spindle-cell sarcomas. Nutrients 10:765PubMedCentralCrossRef

34.

Konishi T, Doki N, Kishida Y, Nagata A, Yamada Y, Kaito S, Kurosawa S, Yoshifuji K, Shirane S, Uchida T, Inamoto K, Toya T, Igarashi A, Najima Y, Kobayashi T, Kakihana K, Sakamaki H, Ohashi K (2019) Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission. Ann Hematol 98:1799–1801PubMedCrossRef

35.

Okada M, Tasaka T, Ikegame K, Aotsuka N, Kobayashi T, Najima Y, Matsuhashi Y, Wada H, Tokunaga H, Masuda S, Utsu Y, Yoshihara S, Kaida K, Daimon T, Ogawa H (2018) A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning. Eur J Haematol 100:335–343PubMedCrossRef

36.

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919PubMedPubMedCentralCrossRef

37.

Nakasone H, Fukuda T, Kanda J, Mori T, Yano S, Kobayashi T et al (2015) Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. Bone Marrow Transplant 50:559–565PubMedCrossRef

38.

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828PubMed

39.

Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217PubMedCrossRef

40.

Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, Ueda Y, Kaida K, Ishii S, Taniguchi K, Okada M, Tamaki H, Okumura H, Kaya H, Kurokawa T, Kodera Y, Taniguchi S, Kanda Y, Ogawa H (2015) Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: a prospective multicenter phase I/II study in Japan. Biol Blood Marrow Transplant 21:1495–1505PubMedCrossRef

41.

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15:367–369PubMedPubMedCentralCrossRef

42.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458PubMedCrossRef

43.

Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V et al (2016) The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica 2101:1426–1433CrossRef

44.

Fuji S, Takano K, Mori T, Eto T, Taniguchi S, Ohashi K, Sakamaki H, Morishima Y, Kato K, Miyamura K, Suzuki R, Fukuda T (2014) Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. Bone Marrow Transplant 49:1505–1512PubMedCrossRef

45.

Doney K, McMillen K, Buono L, Deeg HJ, Gooley T (2019) Impact of body mass index on outcomes of hematopoietic stem cell transplantation in adults. Biol Blood Marrow Transplant 25:613–620PubMedCrossRef

46.

Guieze R, Lemal R, Cabrespine A, Hermet E, Tournilhac O, Combal C et al (2014) Enteral versus parenteral nutritional support in allogeneic haematopoietic stem-cell transplantation. Clin Nutr 33:533–538PubMedCrossRef

47.

Seguy D, Duhamel A, Rejeb MB, Gomez E, Buhl ND, Bruno B, Cortot A, Yakoub-Agha I (2012) Better outcome of patients undergoing enteral tube feeding after myeloablative conditioning for allogeneic stem cell transplantation. Transplantation 94:287–294PubMedCrossRef

48.

Baumgartner A, Bargetzi A, Zueger N, Bargetzi M, Medinger M, Bounoure L, Gomes F, Stanga Z, Mueller B, Schuetz P (2017) Revisiting nutritional support for allogeneic hematologic stem cell transplantation—a systematic review. Bone Marrow Transplant 52:506–513PubMedCrossRef

49.

Tischer J, Engel N, Fritsch S, Prevalsek D, Hubmann M, Schulz C, Zoellner AK, Bücklein V, Lippl S, Reibke R, Rieger CT, Ledderose G, Stemmler HJ, Hiddemann W, Schmid C, Hausmann A (2014) Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant 49:895–901PubMedCrossRef

50.

Yeh SP, Lin CC, Lin CH, Lo WC, Chen TT, Lo WJ, Lin CL, Chiu CF (2015) Second haploidentical peripheral blood stem cell transplantation for treatment of acute leukemia with relapse after first allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 50:1001–1003PubMedCrossRef

51.

Konuma T, Kato S, Ooi J, Ebihara Y, Mochizuki S, Ishii H, Takei T, Oiwa-Monna M, Tojo A, Takahashi S (2016) Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation. Leuk Lymphoma 57:103–109PubMedCrossRef

Titel: Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation
verfasst von: Satoshi Kaito
Atsushi Wada
Hiroto Adachi
Ryosuke Konuma
Yuya Kishida
Akihito Nagata
Tatsuya Konishi
Yuta Yamada
Takuma Kumagai
Kota Yoshifuji
Junichi Mukae
Megumi Akiyama
Kyoko Inamoto
Takashi Toya
Aiko Igarashi
Yuho Najima
Hideharu Muto
Takeshi Kobayashi
Kazuhiko Kakihana
Kazuteru Ohashi
Hisashi Sakamaki
Noriko Doki
Publikationsdatum: 10.06.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 7/2020
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04089-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction

LPS-induced expression and release of monocyte tissue factor in patients with haemophilia

Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab

Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19

COVID-19 infection associated with autoimmune hemolytic anemia

Functional polymorphisms of BCL11A and HBS1L-MYB genes affect both fetal hemoglobin level and clinical outcomes in a cohort of children with sickle cell anemia

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin